Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

Inclusion Criteria: * Clinical stage I-III HER2 positive breast cancer treated with neoadjuvant chemotherapy including HER-2 directed treatment for at least 12 weeks. * Residual invasive carcinoma in the breast or axillary nodes in the final pathology from resected tumor following neoadjuvant chemotherapy. * Completed last cycle of cytotoxic chemotherapy (excluding ado-trastuzumab emtansine \[T-DM1\]) or radiation \> 30 days with resolution of all acute toxic effects of prior therapy to grade ≤ 2 (except alopecia) * Currently on HER-2 targeted therapy (eg; trastuzumab +/- pertuzumab or T-DM1) per standard of care or has completed HER-2 targeted therapy less than 6 months ago * Age ≥ 18 years. * Eastern Cooperative Group (ECOG) performance status 0 or 1. * Must have normal organ and marrow function as defined below: * Absolute neutrophil count (ANC) ≥ 1,000/ μL * Platelets ≥ 75,000/ μL * Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN), except patients with Gilbert's syndrome in whom total bilirubin must be \<3.0 mg/dL * AST/ALT ≤ 3 x institutional upper limit of normal (ULN) * Creatinine ≤ 1.5 x institutional upper limit of normal (ULN) * Hemoglobin A1C \<6.5% * Left ventricular ejection fraction (LVEF) above institutional lower limit of normal (by echocardiogram or MUGA scan within 90 days of registration). * Females of child-bearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test at screening,…